Overview of Findaler-D

Quick Facts

Property	Description
Active ingredient	Cetirizine Hydrochloride, Pseudoephedrine
Form	Oral preparation (Tablet)
Pharmacological class	Antihistamine-decongestant combination
General purpose	Relieves allergic symptoms and nasal congestion
Origin	Synthetic

What is Findaler-D and What Type of Medicine Is It?

Findaler-D is classified as a Fixed-Dose Combination (FDC) medicine, representing a strategic blend of two distinct active compounds delivered as an oral preparation, typically a tablet. The medication belongs to the pharmacological class of Antihistamine-decongestant combinations, utilized for systemic use to manage symptoms associated with allergic responses and respiratory congestion. This synthetic formulation is widely clinically recognized for combining the convenience of two necessary therapies into a single entity, which differentiates it from single-agent medications. This design is often positioned for patients requiring comprehensive, multi-symptom relief.

Composition: Active Ingredients and Pharmacological Classes

The core of Findaler-D is its dual active composition: Cetirizine Hydrochloride and Pseudoephedrine. Cetirizine Hydrochloride is defined as a second-generation antihistamine that acts as a selective peripheral Histamine H1 receptor antagonist. The combination is characterized by the coupling of an effective H1 receptor antagonist with a nasal decongestant. Pseudoephedrine, in contrast, is a sympathomimetic amine that is clinically categorized as a decongestant. Both compounds are essential, with the antihistamine managing immune response triggers and the decongestant focusing on physical symptoms of congestion.

General Purpose of the Combined Formulation

The overall purpose of Findaler-D is to suppress the allergic cascade while reducing physical nasal obstruction. The Cetirizine Hydrochloride component provides Histamine H1 receptor blockade, which targets the source of symptoms such as itching and sneezing. Concurrently, the Pseudoephedrine component achieves vasoconstriction within the nasal lining, the physiological action responsible for reduction of mucosal swelling and relief from nasal congestion. This synchronized action aims to provide a comprehensive management strategy by addressing both the allergic trigger and its resultant physical discomfort, a key factor in improving the quality of life for adolescent and adult patients dealing with simultaneous allergy symptoms and congestion.

Regulatory References

Cetirizine Hydrochloride

What side effects are possible with Findaler-D?

Possible side effects and safety information

The safety profile of Findaler-D, a combination of Cetirizine and Pseudoephedrine, is defined by regulatory authorities through specific adverse reaction classifications and restrictions.

Adverse Reaction Frequency Classification

Side effects are classified based on the frequency observed in clinical data, which helps define the expected risk profile.

Classification	Examples of Reactions
Common (based on Cetirizine)	Somnolence (drowsiness), dry mouth, fatigue
Uncommon (based on Cetirizine)	Agitation, paresthesia, pruritus (itching), rash

Serious reactions are officially documented to include rare but clinically significant events such as Anaphylactic shock and severe Hypersensitivity reactions. Events like clinically significant hypertension and cardiac arrhythmias are also noted due to the decongestant component. Additionally, rare cerebrovascular events like PRES (Posterior Reversible Encephalopathy Syndrome) and RCVS (Reversible Cerebral Vasoconstriction Syndrome) have been associated with pseudoephedrine-containing products.

Safety Considerations and Restrictions

Specific safety statements are provided for particular patient groups and concurrent conditions:

Older Adults: Increased caution is advised due to a higher potential for central nervous system effects.
Renal Impairment: The drug is used with caution as clearance of the active components may be reduced.
Cardiovascular Conditions: Use is contraindicated in individuals with severe or uncontrolled hypertension or severe coronary artery disease.
Drug Interactions: The medicine is contraindicated for use with, or within 14 days of discontinuing, Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

Overdose Manifestations and Clinical Signs

An overdose of Findaler-D can present with a combination of stimulatory and depressant effects on the Central Nervous System (CNS), reflecting the dual active components. Documented signs include a range from restlessness, irritability, and tremor to profound somnolence, confusion, and stupor.

Cardiovascular and systemic manifestations are also officially described. These include tachycardia and a fast, slow, or irregular heartbeat or pulse, as well as changes in breathing patterns. Gastrointestinal symptoms like nausea and diarrhea are also documented in regulatory labeling. The potential for severe neurological complications such as convulsions (seizures) is officially noted.

When to Seek Urgent Medical Help

Due to the risk of severe CNS, cardiac, and respiratory instability, immediate medical attention is required for any suspected overdose. The official regulatory instruction is to get medical help right away and to contact a Poison Control Center right away.

Management of overdose is primarily symptomatic and supportive treatment, as no specific antidote is known. Official labeling notes that the cetirizine component is not effectively removed by dialysis. Regulatory information further points out that elderly patients and adolescents from 12 years old may be at an increased risk for specific CNS effects during an overdose.

Therapeutic Uses of Findaler-D

The therapeutic role of Findaler-D involves providing symptomatic relief during episodes of upper respiratory allergies, commonly known as allergic rhinitis or hay fever, in adults and adolescents aged 12 years and older. The medication is commonly used across conditions presenting with acute or disruptive episodes of upper respiratory allergies.

Dual Relief for Allergic Rhinitis and Congestion

This medication is applied across domains where additional symptomatic support is needed, primarily when patients experience both the irritations of an allergic response and notable nasal obstruction. It helps address symptom clusters that interfere with daily comfort, such as persistent sneezing, runny nose, ocular itching, and nasal congestion. This combined approach provides support that helps ease the overall symptom burden during symptomatic phases.

Management of Nasal and Sinus Pressure

Findaler-D is generally relevant in situations where nasal and sinus congestion is a significant manifestation. It is used for managing the feeling of stuffiness, reduced airflow, and associated pressure. This benefit supports the patient during difficult episodes by assisting with maintaining functional stability and contributes to general well-being during symptomatic phases when symptoms are more noticeable.

Quick Fact: Relief for Compounded Allergy Symptoms

The medicine assists with managing the simultaneous presentation of symptoms related to inflammatory or irritative states (itching, running, sneezing) and symptoms related to heightened physiological activity (nasal blockage, pressure) that characterize hay fever and seasonal allergies.

Regulatory References

US National Library of Medicine DailyMed data

Eligibility and Restrictions for Use

Findaler-D is approved for use only by adults and adolescents aged 12 years and older for temporary relief of allergic symptoms and nasal congestion. Use is not recommended for children under 12 years of age as the concentration of the decongestant component exceeds recommended pediatric limits.

Contraindications and Restrictions

Official regulatory labeling dictates that Findaler-D must not be used by individuals with a known allergy to the product, its ingredients, or to the related antihistamine hydroxyzine.

Absolute contraindications include patients currently taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of stopping one. Use is also prohibited for patients with severe high blood pressure (hypertension), severe coronary artery disease, narrow-angle glaucoma, or conditions resulting in urinary retention.

Use in Specific Populations

Organ Impairment: Patients with kidney disease or liver disease must consult a health professional, as a different dose may be required due to altered drug clearance.
Older Adults (65+): This group must ask a doctor due to the potential for decreased kidney function.
Pregnancy and Lactation: Pregnant individuals must ask a health professional before use. Use is not recommended for individuals who are breast-feeding.

What should I know about interactions with other medicines?

Official Interaction Statements

Classification	Interacting Substances/Category	Regulatory Outcome
Contraindicated	Monoamine Oxidase Inhibitors (MAOIs)	Prohibited due to high risk of severe blood pressure increase.
Contraindicated	Vasoconstrictive Ergot Alkaloids	Prohibited due to risk of enhanced sympathetic effects and significant hypertension.
Pharmacodynamic	Alcohol and CNS Depressants	Additive effects leading to increased reduction in alertness and CNS performance.
Pharmacokinetic	Theophylline (400 mg dose)	Decreases the clearance of Cetirizine, resulting in a measurable increase in systemic exposure.
Pharmacodynamic	Antihypertensive Agents	The sympathomimetic component can diminish the therapeutic effectiveness of these medicines.

Interaction-Related Restrictions and Constraints

The regulatory labeling defines strict conditions for concurrent use. Co-administration with MAOIs is forbidden; a mandatory separation period of at least 14 days must elapse after stopping MAOI therapy before Findaler-D can be initiated. Concurrent use is officially not advised with Cardiac Glycosides due to a documented risk of increased ectopic activity.

Separately, Antacids have been shown to increase the absorption of Pseudoephedrine, while Kaolin has been documented to reduce its absorption. For specific populations, the clearance of both active ingredients is documented to be reduced in patients with renal impairment, which increases the potential for interactions at standard dosage levels.

Mechanism of Action

Findaler-D contains two active components: cetirizine and pseudoephedrine.

Cetirizine acts as a selective antagonist of the peripheral histamine H1 receptor. It competitively binds to the H1 receptor sites on effector cells, primarily in the smooth muscle of the bronchi, blood vessels, and gastrointestinal tract, as well as on vascular endothelial cells. By occupying these receptors, cetirizine prevents the binding of endogenous histamine. The downstream consequence is the modulation of histamine-mediated intracellular signaling, which results in reduced capillary permeability and decreased extravasation of fluid into tissues. Cetirizine also exhibits H1-independent anti-inflammatory properties by modulating the release of certain cytokines and chemokines, and inhibiting eosinophil chemotaxis.

Pseudoephedrine functions as an indirect-acting sympathomimetic amine and a direct agonist at alpha-adrenergic receptors. Its primary systemic effect is vasoconstriction via alpha1 receptor activation on precapillary arterioles and venules in the nasal mucosa. This arteriolar constriction decreases blood flow, leading to physiological modulation of blood volume and pressure within the vascular beds of the upper respiratory mucosa.

Dosage and Administration Information

Official Administration Protocol

Findaler-D is administered solely by the oral route as an extended-release tablet, which delivers the fixed combination of 5 mg Cetirizine Hydrochloride and 120 mg Pseudoephedrine Hydrochloride. The standard usage protocol for adults and adolescents 12 years of age and older is one tablet taken every 12 hours, establishing a routine twice-daily regimen. Clinical instructions specify that the total intake should not exceed two tablets in any 24-hour period. The medication is designated for the temporary management of symptoms.

Preparation and Handling

The administration of the tablet is subject to specific handling conditions mandated by its prolonged-release formulation. The tablet must be swallowed whole with liquid and must not be crushed, broken, or chewed under any circumstances. This restriction is necessary to ensure the 12-hour duration of action provided by the extended-release design. The tablet may be consumed with or without food.

Population-Specific Use

Usage guidelines detail required dose modifications for specific patient groups. Individuals with moderate renal impairment or hepatic insufficiency are required to have their dose interval adjusted, and a reduced dose, such as one tablet taken daily, is often recommended based on organ function. Furthermore, the fixed-dose combination is not authorized for use in pediatric patients younger than 12 years of age.

Recent Clinical Evidence

Research evidence / Overview of studies for Findaler-D

Evidence for Use in Allergic Rhinitis with Congestion

The research base for Findaler-D was developed through clinical evaluations, primarily using Randomized Controlled Trials (RCTs). These short-term RCTs were applied in studies examining patient-reported experiences for use in conditions characterized by combined allergy symptoms and nasal obstruction, which typically presents with fluctuating or episodic manifestations. These studies explore how symptoms change over time when using the combination medicine.

Study Designs and Measured Outcomes

The available research includes robust study designs, such as double-blind, placebo-controlled trials. Research monitored Total Nasal Symptom Scores (TNSS), which are composite outcomes related to physical discomfort like sneezing, nasal itching, and runny nose. Studies also explored the severity of nasal congestion or stuffiness, which is an outcome linked to physiological strain. Furthermore, researchers examined objective measurements of nasal flow and nasal patency to evaluate the physiological change associated with congestion.

Comparison Research

Studies were conducted during periods of increased symptom activity to evaluate the combination medicine against its single active components. This comparison research helps contextualize how the two-ingredient formulation was observed in some studies compared to when the antihistamine (Cetirizine) was studied alone. This comparison was relevant in trials assessing short-term or episodic symptom patterns and research describes patterns observed when comparing the combination to monotherapy.

Duration of Evidence: Short-Term Trials and Follow-Up

Research exploring short-term symptom changes was a primary focus of the clinical program for Findaler-D. Many studies monitored responses over defined time intervals. Core efficacy trials commonly used defined treatment periods of up to four weeks. These short-term trials provided insight into changes measured during the initial study period.

Evidence Gaps and Research Uncertainty

The current body of evidence contributes to understanding short-term symptom patterns but is subject to several limitations. The follow-up durations were limited across many of the core studies, meaning that long-term effects are not fully established. Existing research provides context, but not individual predictions, and the results apply only to the specific populations studied. Dedicated data for older adults (geriatric patients) remain insufficient in the primary efficacy research.

Key Studies & References

Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets, 5 mg/120 mg (FDA Approval Package/Labeling)

Frequently Asked Questions (FAQ)

Common questions about Findaler-D (FAQ)

Q: Does Findaler-D have any known long-term side effects?

Research evidence for Findaler-D was primarily derived from short-term studies, with core efficacy trials commonly monitoring patient response over periods up to four weeks. According to official product information, the results from these trials contribute to understanding short-term symptom changes. However, the full scope of potential long-term effects is described in regulatory documents as not fully established in this initial research.

Q: Is Findaler-D appropriate for older adults or seniors?

Official documents advise increased caution for older adults (seniors) because there is a higher potential for central nervous system effects in this population. The regulatory instructions also note that older adults may experience decreased kidney function, which could affect how the ingredients are cleared from the body. Because of these factors, official guidelines state that this group is advised to consult a health professional before use.

Q: Is Findaler-D the same as similar medicines without the 'D'?

Findaler-D is classified as a Fixed-Dose Combination containing two active ingredients: an antihistamine (Cetirizine) and a decongestant (Pseudoephedrine). Similar medicines without the 'D' designation typically contain only the antihistamine component. Regulatory guidance indicates that taking both the combination product and the single-component medicine together may result in a greater than recommended amount of a certain ingredient.

Q: Is Findaler-D a controlled substance?

Products containing the decongestant component of Findaler-D are subject to specific legal requirements and purchase restrictions placed by regulatory bodies. These restrictions include sales limits and required photo identification due to the regulatory status related to the potential for illicit substance manufacture.

Q: How quickly should I expect Findaler-D to start working?

Studies examining the drug’s performance have reported that the onset of action for the combination formulation of the active ingredients is approximately 30 minutes. This measure represents the approximate time it takes for the ingredients to begin working in the body.

Q: Do I need to take Findaler-D every day for it to be effective?

The standard usage protocol establishes a routine of one extended-release tablet taken every 12 hours for the temporary management of symptoms. The medication is generally used as needed when allergy and congestion symptoms are present.

Q: What should I do if I miss a scheduled dose of Findaler-D?

Regulatory guidance for products containing the decongestant component describes a protocol where if a regular dose is missed, it may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the protocol advises skipping the missed dose entirely. This is done to prevent the possibility of taking a double dose.

Q: Can I stop taking Findaler-D suddenly without any issues?

Regulatory safety updates for the antihistamine component note that stopping consistent, daily use after long periods may result in the sudden appearance of severe symptoms. This has been reported as intense itching (pruritus).

Q: Why do some people report trouble falling asleep after taking Findaler-D?

The official safety profile lists both agitation and insomnia (sleep problems) as reported effects of the medication. This is commonly associated with the central nervous system stimulant action of the decongestant component (Pseudoephedrine).

Q: Does Findaler-D affect my mood, anxiety levels, or overall mental state?

Official safety information notes that agitation is classified as an uncommon adverse reaction associated with this product. Since the decongestant component is a sympathomimetic amine, it is associated with central nervous system stimulant effects which may affect a person's overall mental state.

Q: Does Findaler-D interact with caffeine or large amounts of coffee?

Official documentation for the decongestant component advises caution regarding concurrent use with other central nervous system stimulants like caffeine. Both the decongestant and caffeine can increase blood pressure and heart rate. Regulatory caution indicates that combining them may enhance these effects, particularly for individuals with existing heart conditions or high blood pressure.

Q: Are there any specific foods or drinks that should be avoided when taking Findaler-D?

The extended-release tablet is officially allowed to be consumed with or without food. However, regulatory labeling does note that Antacids can increase the absorption of one active ingredient, and Kaolin has been documented to reduce the absorption of one ingredient.

Q: What herbal supplements are known to interact with Findaler-D?

Regulatory bodies generally advise that there is insufficient official information available on the safety of taking most herbal remedies and supplements with products containing the decongestant component. This is because these products are often not subjected to the same standardized testing as pharmacy or prescription medicines.

Q: Can I take over-the-counter pain relievers or cold medicines at the same time as Findaler-D?

Official guidance advises reviewing the labels of all other cold, allergy, or flu medicines for consistency before use. This is to avoid taking duplicate active ingredients, such as additional antihistamines or decongestants, which could lead to consuming amounts higher than recommended and potentially causing side effects.

Q: What does the medical community mean when they refer to Findaler-D as 'dual-action'?

The medicine is classified in official documents as a Fixed-Dose Combination of two distinct active compounds, an antihistamine and a decongestant. This 'dual-action' design provides a comprehensive strategy for managing combined allergic symptoms and nasal congestion in a single entity.

Q: Is there a risk of a 'rebound' effect when using Findaler-D for an extended period?

Regulatory data notes that after stopping long-term daily use of the antihistamine component, severe symptoms like intense itching (pruritus) may occur. While 'rebound congestion' is typically associated with nasal sprays, the potential for a rebound mechanism related to the oral decongestant component is noted.

Q: Is Findaler-D considered a medicine that could be addictive or habit-forming?

The decongestant component is chemically similar to a stimulant and has been associated with risks of misuse and dependency when taken in doses higher than those recommended. Due to these potential risks, regulatory bodies have placed legal restrictions on its sale.

Q: Does the 'D' in Findaler-D signify a decongestant component?

Findaler-D is officially classified as an Antihistamine-decongestant combination. The letter 'D' is commonly used in similar product names within this pharmacological class to indicate the presence of the decongestant component (Pseudoephedrine).

How should Findaler-D be stored and disposed of?

The storage and disposal of Findaler-D (Cetirizine/Pseudoephedrine) must strictly follow the conditions defined in official regulatory labeling to maintain product stability and ensure public safety.

Storage Requirements

The medication must be stored at 20 C to 25 C (68 F to 77 F), which aligns with USP Controlled Room Temperature. The product must be kept from freezing and protected from excessive heat and moisture. Tablets should remain in their tightly closed, original container to protect integrity.

Disposal and Child Safety

The tablets must be kept out of the sight and reach of children to prevent accidental ingestion, with safety caps securely locked. For disposal, unused or expired medication should be discarded according to local regulations. If a drug take-back program is unavailable, non-flushable medicines like Findaler-D must be mixed with an unappealing substance and placed in a sealed bag before being thrown in the household trash, as specified by regulatory guidance.

Findaler-D